Description

Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage[1].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-C6482H10006N1714O2022S44(C42H58ClN3O14S3)n-Citation–References-[1]Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784.-CASNumber-1453084-37-1-MolecularWeight-150000 (average)-Compound Purity-99.90-SMILES-[Mirvetuximab soravtansine]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related